Relay Therapeutics Announces Planned Public Offering of Common Stock Page 1

CAMBRIDGE, Mass., Sept. 9, 2024 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company revolutionizing the drug discovery process by combining cutting-edge computational and experimental technologies, today announced that it has commenced an underwritten public offering of $200 million of its common stock. Relay Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the common stock offered in the public offering. All shares in the proposed offering are to be sold by Relay Therapeutics.

Goldman Sachs & Co. LLC, TD Cowen, Stifel and BofA Securities are acting as joint bookrunners for the proposed offering. Raymond James is acting as co-manager. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or the actual size or terms of the offering.